Our data demonstrated that the eupatilin-induced increase in the sub-G1 phase was found to be more sensitive with the absence of SERPINB11 in ES2 and OV90 cells, and the combination of siSERPINB11 and eupatilin significantly reduced the G1 phase in ES2 cells compared to siSERPINB11 alone, revealing that SERPINB11 is a major protein target for triggering anticancer activity in ovarian cancer (Figure 6F). This evidence concerns the gene SERPINB11 and ovarian cancer.